European legislation regulating the marketing authorisation of medical products states that results from clinical trials that do not meet the ethical requirements of Good Clinical Practice, cannot legally be used by an applicant to justify its application, irrespective of whether the trial was...

In the aftermath of the financial crises, questions have been raised as to why there were significant differences in the denominator of the calculation of risk-weighted assets (RWAs). The EBA and other international bodies have already conducted significant work on the comparability of capital...